Nancy Lurker - 10 Jul 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Executive Vice Chair, Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
10 Jul 2024
Net transactions value
$0
Form type
4
Filing time
12 Jul 2024, 17:03:25 UTC
Previous filing
04 Jun 2024
Next filing
26 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +11,111 +13% $0.000000 94,462 10 Jul 2024 Direct
holding EYPT Common Stock 126,889 10 Jul 2024 By Family Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -11,111 -33% $0.000000 22,223 10 Jul 2024 Common Stock 11,111 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2 The restricted stock units vests in three ratable annual installments beginning July 10, 2024.